Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses: Results of 32 Clinical Trials.
Wang SV, Schneeweiss S; RCT-DUPLICATE Initiative; Franklin JM, Desai RJ, Feldman W, Garry EM, Glynn RJ, Lin KJ, Paik J, Patorno E, Suissa S, D'Andrea E, Jawaid D, Lee H, Pawar A, Sreedhara SK, Tesfaye H, Bessette LG, Zabotka L, Lee SB, Gautam N, York C, Zakoul H, Concato J, Martin D, Paraoan D, Quinto K. Wang SV, et al. Among authors: jawaid d. JAMA. 2023 Apr 25;329(16):1376-1385. doi: 10.1001/jama.2023.4221. JAMA. 2023. PMID: 37097356 Free PMC article.
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.
Ghosh N, Eyre TA, Brown JR, Lamanna N, Manzoor BS, Coombs CC, Tuncer HH, Ujjani C, Leslie LA, Roeker LE, Davids MS, Rhodes JM, Skarbnik AP, Sinai W, Fleury I, Hill BT, Martinez-Calle N, Barr PM, Jawaid D, Emechebe N, Pearson L, Lansigan F, Choi Y, Jensen CE, Fakhri B, Stephens DM, Marx SE, Schuster SJ, Coyle M, Pivneva I, Watson T, Guerin A, Shadman M. Ghosh N, et al. Among authors: jawaid d. Am J Hematol. 2024 Dec 19. doi: 10.1002/ajh.27563. Online ahead of print. Am J Hematol. 2024. PMID: 39698781 No abstract available.
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.
Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Sivchev L, Niemann CU, Schwarer A, Loscertales J, Weinkove R, Strumberg D, Kilfoyle A, Manzoor BS, Jawaid D, Emechebe N, Devine J, Boyer M, Runkel ED, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K. Al-Sawaf O, et al. Among authors: jawaid d. Blood. 2024 Oct 31;144(18):1924-1935. doi: 10.1182/blood.2024024631. Blood. 2024. PMID: 39082668 Free PMC article. Clinical Trial.
Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting.
Huntington SF, Manzoor BS, Jawaid D, Puckett JT, Emechebe N, Ravelo A, Kamal-Bahl S, Doshi JA. Huntington SF, et al. Among authors: jawaid d. J Manag Care Spec Pharm. 2024 Oct;30(10):1106-1116. doi: 10.18553/jmcp.2024.24049. Epub 2024 Jul 24. J Manag Care Spec Pharm. 2024. PMID: 39046941 Free PMC article.
Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.
Fakhri B, Emechebe N, Manzoor BS, Jawaid D, Alhasani H, Edwards M, Tuncer HH. Fakhri B, et al. Among authors: jawaid d. JCO Oncol Pract. 2024 Aug;20(8):1132-1139. doi: 10.1200/OP.23.00630. Epub 2024 Apr 16. JCO Oncol Pract. 2024. PMID: 38626366 Free PMC article.